Otoferlin Gene-mediated Hearing Loss Natural History Study

Last updated: October 21, 2024
Sponsor: Akouos, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Deafness

Hearing Impairment

Hearing Loss

Treatment

Natural History Study

Clinical Study ID

NCT05572073
AK-OTOF-NHS-002
  • Ages < 44
  • All Genders

Study Summary

This is a retrospective and prospective longitudinal study in participants with Otoferlin Gene-Mediated Hearing Loss.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Clinical presentation of bilateral sensorineural hearing loss (SNHL), includingauditory neuropathy (AN) / auditory neuropathy spectrum disorder (ANSD) phenotype ormedical history of AN / ANSD phenotype earlier in life

  2. Mutation(s) in the otoferlin gene

  3. Able and willing to comply with all study requirements, as evidenced by successfulcompletion of the informed consent (and assent, if applicable) process Additional Criteria for Inclusion in the Prospective Phase:

  4. Presence of OAE / CM and absent / abnormal ABRs in at least one ear (that does nothave a cochlear implant) within 12 months prior to or at the Month 0 visit

Exclusion

Exclusion Criteria:

  1. Unwillingness or inability of the potential participant and/or legally authorizedrepresentative to comply with all protocol requirements

  2. Presence of cochlear nerve deficiency and/or cochlear nerve dysplasia Additional Criteria for Exclusion from the Prospective Phase:

  3. Presence of bilateral cochlear implants at the time of record review or plannedwithin the next 6 months

  4. Presence of middle ear or auditory brainstem implant(s) at the time of record reviewor planned within the next 6 months

  5. Any condition that would not allow the potential participant to complete follow-upassessments during the course of the study and/or, in the opinion of theInvestigator, makes the potential participant unsuitable for the study

Note: Potential participants will not be excluded based on their sex, gender, race, or ethnicity

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: Natural History Study
Phase:
Study Start date:
July 14, 2022
Estimated Completion Date:
February 28, 2029

Connect with a study center

  • Murdoch Children's Research Institute

    Parkville, Victoria VIC 3052
    Australia

    Active - Recruiting

  • University Hospital in Tübingen

    Tübingen, 72076
    Germany

    Active - Recruiting

  • Sant Joan de Déu Barcelona Hospital

    Esplugues de Llobregat, Barcelona 08950
    Spain

    Active - Recruiting

  • National Taiwan University Hospital

    Taipei, 100
    Taiwan

    Active - Recruiting

  • University College London

    London, NW1 2PG
    United Kingdom

    Active - Recruiting

  • University of Iowa

    Iowa City, Iowa 52242
    United States

    Active - Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Active - Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37232-8605
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.